Clinical Trials Directory

Trials / Sponsors / Dan Zandberg

Dan Zandberg

Academic / Other · 9 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
RecruitingPulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Phase 22023-10-03
RecruitingAnti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Melanoma, NSCLC, Hepatocellular Carcinoma
Phase 22020-09-14
Active Not RecruitingHPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Sq
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Phase 22020-07-06
Active Not RecruitingStudy of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Renal Cell Carcinoma, Melanoma, Solid Tumor
Phase 1 / Phase 22020-06-11
CompletedPersonalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunoth
Squamous Cell Carcinoma of the Head and Neck
Phase 22020-05-14
RecruitingStudy of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab
Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 22019-12-20
CompletedEvaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Advanced Solid Tumors, NSCLC, Bladder Cancer
Phase 32019-11-15
CompletedPembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cance
Head and Neck Squamous Cell Carcinoma
Phase 22016-05-31
CompletedReirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of t
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
Phase 22016-03-09